Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P04062
UPID:
GBA1_HUMAN
Alternative names:
Acid beta-glucosidase; Alglucerase; Beta-glucocerebrosidase; Beta-glucosylceramidase 1; Cholesterol glucosyltransferase; Cholesteryl-beta-glucosidase; D-glucosyl-N-acylsphingosine glucohydrolase; Glucosylceramidase beta 1; Imiglucerase; Lysosomal cholesterol glycosyltransferase; Lysosomal galactosylceramidase; Lysosomal glycosylceramidase
Alternative UPACC:
P04062; A8K796; B7Z5G2; B7Z6S1; J3KQG4; J3KQK9; Q16545; Q4VX22; Q6I9R6; Q9UMJ8
Background:
Lysosomal acid glucosylceramidase, known by names such as Acid beta-glucosidase and Imiglucerase, plays a pivotal role in the lysosomal degradation of glucosylceramide into ceramide and glucose. This enzyme is essential for the turnover of cellular membranes and the metabolism of complex lipids.
Therapeutic significance:
Mutations in this enzyme lead to Gaucher disease, a lysosomal storage disorder with varying forms and severities, including neuronopathic and non-neuronopathic types. Its involvement in Parkinson disease highlights its broader impact on neurodegenerative disorders, making it a target for therapeutic intervention.